FDA Approves Metvixia
FDA Approves Metvixia for Actinic Keratosis
Methyl aminolevulinate is a novel, non-invasive treatment which combines the local application of cream, selectively absorbed into abnormal cells, and illumination with a proprietary red light source (CureLight/Aktilite) to activate the drug for the photodynamic treatment of sun-induced pre-cancerous skin lesions (actinic keratosis) .Posted: July 2004
Related articles
- Photocure Receives FDA Approval for Metvixia/Aktilite Photodynamic Therapy - June 27, 2008
- U.S. New Drug Application Approval Expected for Metvix - June 17, 2004
Metvixia (methyl aminolevulinate hydrochloride) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
